Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) (Q29620605)

From Wikidata

Jump to navigation Jump to search

scientific article published in The Lancet

Language	Label	Description	Also known as
English	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)	scientific article published in The Lancet

Statements

scholarly article

0 references

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Thatcher N

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Chang A

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Parikh P

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Rodrigues Pereira J

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Ciuleanu T

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

von Pawel J

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Thongprasert S

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Tan EH

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Pemberton K

9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Archer V

10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Carroll K

11

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

language of work or name

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

366

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

1527-37

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

9496

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiplicity in randomised trials II: subgroup and interim analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967625-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)67625-8

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16257339

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29620605&oldid=2089984825"